Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BRIEF-Sun Pacific Holding Corp Announces MOU With Atlas Transit Solutions To Enhance Outdoor Advertising Structures
Not sure about your math. I counted 36 days in the least 130 days that there was more volume than today.
I think the highest volume day was 689k... a month or so ago.
It seems to me your anti-Chris Nelson bias is keeping your from seeing things objectively.
Like it or not QSAM it's becoming something remarkable. I've already taken my cost off the table and am buckled in for the ride.
Not sure about your math. I counted 36 days in the least 130 days that there was more volume than today.
I think the highest volume day was 689k... a month or so ago.
It seems to me you're anti-Chris Nelson bias is keeping your from seeing things objectively.
Like it or not QSAM it's becoming something remarkable. I've already taken my cost off the table and am buckled in for the ride.
Stock is down 10% on the largest trading volumes of the day.. this came after the news was released..
-Chuck
Visit there or call. You can't talk to anyone other than Chris Nelson.
-Chuck
I just pulled this off their website.
QSAM Biosciences, Inc.
9442 N Capital of Texas Hwy, Plaza 1, Ste 500
Austin, TX 78759
512.343.4558
info@qsambio.com
QSAM keeps adding links into the chain to almost guarantee success.
They've added top-tier board members and now announce signing another Option Agreement to license yet another "promising Cancer Drug therapy."
Some posters can't see anything good... I have a difficult seeing anything bad.
Go QSAM!!
News Release Today: QSAM Biosciences Seeks to Expand Radiochemical Assets; Signs Option Agreement to License its Second Promising Cancer Therapy
Austin, Texas, March 17, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM) announced today that it has signed an Exclusive Option Agreement with IsoTherapeutics Group, LLC to allow the Company a 120-day period to perform diligence and negotiate a worldwide, exclusive license agreement for a pre-clinical staged radiochemical therapy called BetaBrach™.
BetaBrach is a brachytherapy, a cancer treatment where radioactive implants are inserted directly into diseased tissue to eradicate the target tumor. BetaBrach uses beta radiation (Yyttrium-90) chemically formulated to significantly reduce migration to non-targeted healthy tissue. It has been used extensively in numerous small animal laboratory models of cancer as well as in the University of Missouri’s College of Veterinary Medicine to treat large animals with naturally occurring tumors with very promising results. Such therapy could be used to treat many types of cancer in humans, including breast and prostate.
“This is an important step in our strategy to build a pipeline of radiochemical assets to develop and commercialize for critical and high unmet medical needs, such as cancer,” stated Douglas R. Baum, the Company’s CEO and Co-Founder. “Delivering a precise and personalized dose of BetaBrach directly to the targeted tumor has the potential to be an optimal treatment option for a broad base of cancer patients, as we believe it can also prevent the debilitating side effects and systemic toxicity associated with current treatments such as chemotherapy.”
The option to license BetaBrach follows the Company’s strategy used to acquire the worldwide rights to CycloSam® (Samarium-153 DOTMP) in 2020 from an IsoTherapeutics affiliated company whose founders created Quadramet® (Samarium-153-EDTMP), one of the first FDA approved and commercially available radiopharmaceuticals.
https://www.otcmarkets.com/stock/QSAM/news/QSAM-Biosciences-Seeks-to-Expand-Radiochemical-Assets-Signs-Option-Agreement-to-License-its-Second-Promising-Cancer-Ther?id=294067
4 or 5? I count 50 on the latest page alone.
Keep believing the name with this history that is only attached to this company because he was given stock for his name and professional career to be used on the webpage.
Show me an address where I can meet him where the business of Qsam is being conducted.. or better yet, a phone number I can call and talk directly with him and the other BOD members...
The sad reality is that no number or address exists...
Ive had dealings with the man pulling the strings of this company.. Chris Nelson for the past 15 years.. I know his history and how he will lie and cheat at the expense of the share holders to enrich himself.
Notice how he won't post his name or career stats.. because he doesn't want you to know the truth.
-Chuck
Quietly gaining strength. News on progress of entering phase 1 trials should not be far away. Lots of confidence in Baum and Piazza. At right time this will make for a nice acquisition target imo, as company works on developing and gaining FDA approval of cancer drug CycloSam, 40x less toxic than counterpart FDA approved drug Quadramet.
Thanks for the great post that is spot on. Looking at the officers and directors of QSAM, it looks more like a NASDAQ biotech than an OTC. There is not one company in FDA Phase 1 with less than a $50 million market cap. QSAM is about $12 million. Doug Baum said publicly the Company hopes to be in FDA Phase 1 trials the first half of 2021. I'm not selling any either.
I for one have not sold a share. In fact I’ve been adding and have a sizable position, and am excited about what QSAM is doing with improving upon a 23 year old cancer drug with the same doctors involved in the drug’s improvement and evolution. The runway is clear for them to execute and get CycloSam through FDA approval in the appropriate time. There has been very little volume so the sales price is somewhat meaningless until there is more liquidity in the trading. Patience is key as will news updates be by the company on progress. I am pretty confident Chris Nelson is not Oz driving the actual execution of the business plan. My trust is in CEO Baum, Chairman Piazza and the doctors involved in developing the drug, not Nelson.
I'm going to go with Dr. Link over someone fraudulently using the ex-owner of the Oakland A's name. Let's look at Dr; Link's abbreviated bio again:
"Dr. Link brings decades of biotech and drug development experience to QSAM. He currently serves on the executive committee of the Board of Directors at NovaScan Inc., a clinical-stage company focused on cancer detection; and is the founder and President of biotech startup Syncromune. Previously, Dr. Link was the CEO, CSO, Chairman, and founder of NewLink Genetics, a NASDAQ-listed immunotherapy company focused on developing novel immuno-oncology product candidates.
During his tenure at NewLink, Dr. Link led a series of collaborative transactions totaling hundreds of millions of dollars with Merck, Roche and the United States government. He also oversaw the collaboration with Merck to develop EVERBO, the first Ebola vaccine to receive FDA approval.
Prior to founding NewLink Genetics, Dr. Link was an attending physician at the National Cancer Institute. He has authored more than 150 peer-reviewed papers. He previously received funding from the National Institute of Health, the National Cancer Institute, the American Cancer Society, and others. Dr. Link received an M.D. from Stanford University, and he attended the Air Force Academy."
What makes you think four or five positive posts over the course of a few weeks are "a significant volume?"
Why does the price always crash a couple days after there is a significant volume of posts here saying how high this is going to go and that its a great buy at this price??
PUMP PUMP PUMP
then nothing......
Guess they were able to move their shares...
-Chuck
Great add to the QSAM board.
“During his tenure at NewLink, Dr. Link led a series of collaborative transactions totaling hundreds of millions of dollars with Merck, Roche and the United States government. He also oversaw the collaboration with Merck to develop EVERBO, the first Ebola vaccine to receive FDA approval.”
Love his FDA approval process and success experiences. Just the type of expertise QSAM needs to take CycloSam through the process to replace the 23 year old drug Quadramet. Obviously time to improve upon an old outdated and harder on the system medication for cancers.
Sounds to me like QSAM is continuing to add heavy hitters to their board of directors and development team.
Dr. Charles L Link definitely qualifies. He's been active in multiple biotech companies and has been a part of bringing numerous drugs to market. He will also serve as the companies "Medical Director."
Here's the Dr. Baum and Company think about Dr. Link:
“Chuck brings extensive experience managing critical research and development programs, leading breakthrough drug approval efforts, and creating significant shareholder value for both publicly-traded and private companies,” said Douglas R. Baum, the Company’s CEO and Co-Founder. “As we enter our next phase of growth, we expect that Chuck’s corporate leadership and drug development expertise will be critical components to driving our success.”
I can't imagine a more qualified or potentially beneficial person to bring on board.
And what does our newest Director, Dr. Link think about CycloSam, QSAM's initial drug candidate??
“The Company’s primary drug candidate, CycloSam® (Samaium-153 DOTMP), shows great promise for treating several highly underserved oncological needs, including potentially primary bone cancers mostly affecting children and young adults. I’m excited about the opportunity to help the Company advance its strategy and development plans as we enter clinical trials this year.”
NEWS 2/16/2021 QSAM Biosciences Appoints Charles J. Link, Jr., M.D., Experienced Biotech Executive and Innovator, to Board of Directors
Austin, TX, Feb. 16, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation nuclear medicines for the treatment of cancer and related diseases, announced today that it has appointed Charles J. Link Jr, M.D., to its Board of Directors effective February 15, 2021. In addition to his role on the Board, Dr. Link will serve part-time as the Company’s Medical Director.
“Chuck brings extensive experience managing critical research and development programs, leading breakthrough drug approval efforts, and creating significant shareholder value for both publicly-traded and private companies,” said Douglas R. Baum, the Company’s CEO and Co-Founder. “As we enter our next phase of growth, we expect that Chuck’s corporate leadership and drug development expertise will be critical components to driving our success.”
“I look forward to working with Doug and the great team at QSAM Biosciences,” stated Dr. Link. “The Company’s primary drug candidate, CycloSam® (Samaium-153 DOTMP), shows great promise for treating several highly underserved oncological needs, including potentially primary bone cancers mostly affecting children and young adults. I’m excited about the opportunity to help the Company advance its strategy and development plans as we enter clinical trials this year.”
Dr. Link brings decades of biotech and drug development experience to QSAM. He currently serves on the executive committee of the Board of Directors at NovaScan Inc., a clinical-stage company focused on cancer detection; and is the founder and President of biotech startup Syncromune. Previously, Dr. Link was the CEO, CSO, Chairman, and founder of NewLink Genetics, a NASDAQ-listed immunotherapy company focused on developing novel immuno-oncology product candidates.
During his tenure at NewLink, Dr. Link led a series of collaborative transactions totaling hundreds of millions of dollars with Merck, Roche and the United States government. He also oversaw the collaboration with Merck to develop EVERBO, the first Ebola vaccine to receive FDA approval.
Prior to founding NewLink Genetics, Dr. Link was an attending physician at the National Cancer Institute. He has authored more than 150 peer-reviewed papers. He previously received funding from the National Institute of Health, the National Cancer Institute, the American Cancer Society, and others. Dr. Link received an M.D. from Stanford University, and he attended the Air Force Academy.
Concurrently with the appointment, the Company accepted the resignation of Scott S. Whitney, a Board member since 2016. “We have been honored and greatly served by Scott’s term on our Board of Directors. He was instrumental in helping our transition into biosciences, and during his five years on our Board, he consistently added important insight, perspective, and overall value to our work. Scott is a leader in the environmental and waste-to-value sectors, and a true professional every respect,” stated Christopher Nelson, fellow Director, and Company General Counsel.
About QSAM Biosciences:
QSAM Bioscience, Inc. holds the worldwide license for CycloSam® (Samaium-153 DOTMP), a clinical-stage novel radiopharmaceutical meant to treat different types of bone cancer and related diseases. QSAM’s initial technology is Samarium-153 DOTMP, aka CycloSam®, a clinical-staged bone targeting radiopharmaceutical? developed by IsoTherapeutics Group LLC, leaders in the nuclear medicine space who also developed FDA-approved and commercially available Quadramet® (Samarium-153 EDTMP), indicated for pain palliation. CycloSam was assigned to IsoTherapeutics Group’s subsidiary, IGL Pharma, Inc.
CycloSam® has already demonstrated preliminary safety and efficacy in animal studies and a single patient FDA-cleared successful human trial performed in 2020. This nuclear technology uses low specific activity Samarium-153 (resulting in far less europium) and DOTMP, a chelator which is believed to eliminate off-target migration and targets sites of high bone turn over making it an ideal agent to treat osteosarcoma or other bone metastases. Osteosarcoma is the most common malignant bone tumor among children and adolescents. Because of its ability to deliver radiation to the skeletal system, it is also believed to be an effective agent to perform bone marrow ablation as pre-conditioning for bone marrow transplantation. This drug candidate utilizes an FDA approved radioisotope combined with a novel chelant that has demonstrated increased efficacy and decreased side effects in animal models. Further, CycloSam® utilizes a streamlined, just-in-time manufacturing process. Given these factors, management believes there is a strong pathway to commercialization.
CycloSam® is cleared by the FDA under an investigator initiated IND to commence human dosing in patients with osteosarcoma and bone metastasis. CycloSam® was also cleared by FDA and successfully used under a single-patient IND to perform bone marrow ablation prior to allogenic marrow transplantation (BMA/T) in 2020.
Legal Notice Regarding Forward-Looking Statements: This news release contains “Forward-looking Statements”. These statements relate to future events or our future financial performance. These statements are only predictions and may differ materially from actual future results or events. We disclaim any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise. There are important risk factors that could cause actual results to differ from those contained in forward-looking statements, including, but not limited to our ability to fully commercialize our technology, risks associated with changes in general economic and business conditions, actions of our competitors, the extent to which we are able to develop new products and markets, the time and expense involved in such development activities, the ability to secure additional financing, the ability to consummate acquisitions and ultimately integrate them, the level of demand and market acceptance of our products, and changes in our business strategies. This is not an offering of securities and securities may not be offered or sold absent registration or an applicable exemption from the registration requirements.
Contact
Christopher Nelson
General Counsel
cnelson@qsambio.com
https://www.otcmarkets.com/stock/QSAM/news/QSAM-Biosciences-Appoints-Charles-J-Link-Jr-MD-Experienced-Biotech-Executive-and-Innovator-to-Board-of-Directors?id=290060
Yes it is. Good value un under $1
I agree with you. QSAM's management team is more like a larger NASDAQ biopharma company. https://qsambio.com/#leadership
I continue to think they're are still better days ahead!
Great trade, man. I'm long since $0.28.
Bid above the offer pre market.
MMID Bid Size Time (ET)
GTSM 0.85 1,000 8:35:10 AM
MMID Ask Size Time (ET)
CSTI 0.81 1,000 8:30:13 AM
It will take off well before they get to phase 3. They are in the process of launching phase 1. The players involved here developed FDA approved Quadramet. The new drug CycloSam bone cancer drug will improve upon this platform. Same doctors developing CycloSam for QSAM that developed Quadramet. This should fast track through approval process. Current market cap is just ~$15M. Compare this to the cap of other companies with drugs in the approval process. Very strong leadership team.
Actually I do. Once this product passes through phase 3 clinicals it's going several dollars higher
u really think this gonna take off?
Nope. I’m dipping too. Good things ahead as they execute their plan. Big getting the financing this week. Will be good tracking their progress on moving CycloSam through the FDA approval process. Cap will grow quickly as they hit their milestones.
These flippers are crazy. Way bigger profits coming
Y'all gonna let me buy this whole dip myself?
There has been so much going on for these guys. Under 1.00 is cheap for now. But in a few weeks I think under 2.00 may be considered cheap
Expecting a nice push today as savvy investors flock in before the weekend, QSAM Is building up for a mega PR release imo $$$ QSAM $$$
So you think a 3 year old venture capital company is coming in to save the day?
That $2.5mil will only cover the executive salaries for a couple years, let alone the cost of Phase 1 trials.
Wait until they release the financials to show how much of the money went towards testing and how much went into the pocket of Chris Nelson.
The company headquarter relocation has less to do with a strategic move by the company and more so because Chris Nelson sold his Palm Beach county house back in Sept 2020 and moved to Austin, Tx.
Typical signs a stock is being pumped: 3-5 new posters show up and relentlessly post positive statements regarding the stock without providing any technical detail. PAID PUMPING 101
-Chuck
I have to say... I was a little dismayed that the conversion price was as low as it was... but encouraged also that these shares were not registered and will need to be held for 6 to 12 months.
Pretty serious money at any rate. Why would a company with obvious experience in the industry put this kind of money in the hands of a company like this?
Only ONE reason!!!
I don't know... it looks to me like they're pretty serious about turning this endeavor into a real company.
$2.5 Million for Phase one Trial...
Changing headquarters of the company from Florida to Austin, TX.
It's all continues sounding pretty good to me.
NEWS QSAM Biosciences Closes Series B Preferred Private Placement; $2.5 Million in New Capital to Fund Upcoming Clinical Trials
01/28/2021
Austin, Texas, Jan. 28, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation nuclear medicines for the treatment of cancer and related diseases, announced today the successful closing of its Series B Preferred Stock private placement in the amount of $2.5 million. The offering was led by Checkmate Capital Group, LLC (“Checkmate Capital”), an investment firm based in California focused on biotechnology investments and other technologies.
Proceeds from the Series B offering, which was over-subscribed, are expected to be used primarily to fund the Company’s upcoming clinical trials for its flagship drug candidate Samarium-153-DOTMP (aka CycloSam®). The Company expects to file its IND with the U.S. Food and Drug Administration (“FDA”) later this quarter to commence Phase 1 trials shortly thereafter.
“We are very pleased with the overwhelming interest in our offering, the proceeds from which will go directly into advancing the development of CycloSam. We are focused on several important value creating milestones in 2021, including commencement of clinical trials for CycloSam for indications that include both primary bone cancer, such as osteosarcoma, and secondary bone cancers that metastasize from the breast, lung, prostate and other areas. This funding will go a long way towards achieving these and other strategic goals,” stated Douglas R. Baum, CEO and Co-Founder of QSAM.
“We are delighted to participate in this offering as a leading shareholder of QSAM. We have been impressed with the unique attributes of CycloSam’s radiologic cancer therapy, which, in animal studies, has demonstrated deep bone penetration followed by rapid exit of radioactive content from the body, as was reinforced by an FDA-approved, compassionate-use single human application,” commented Tom Paschall, CEO of Checkmate Capital. “We have been further impressed with QSAM’s team of experts in nuclear medicine as well as the leading oncology centers with which QSAM is partnered.”
The Series B preferred shares are convertible into an aggregate of approximately 16.6 million common shares and have voting rights alongside the common holders based on this conversion amount. Investors in the offering also received six-month, non-registered warrants to purchase an aggregate of up to 5.8 million shares of common stock at $0.35 per share. For its early investment and efforts to support the funding, Checkmate Capital received a 12-month warrant for 475,000 shares at $0.45 per share.
The Company also announced that it has moved its official headquarters from Florida to Austin, Texas.
About QSAM Biosciences:
QSAM Bioscience, Inc. holds the worldwide license for CycloSam® (Samaium-153 DOTMP), a clinical-stage novel radiopharmaceutical meant to treat different types of bone cancer and related diseases. QSAM’s initial technology is Samarium-153 DOTMP, aka CycloSam, a clinical-stage bone targeting radiopharmaceutical? developed by IsoTherapeutics Group LLC, leaders in the nuclear medicine field who also developed FDA-approved and commercially available Quadramet® (Samarium-153 EDTMP), indicated for pain palliation. IsoTherapeutics Group LLC assigned the CycloSam patents to its subsidiary, IGL Pharma, Inc.
CycloSam has already demonstrated preliminary safety and efficacy in animal studies and a single patient FDA-cleared successful human trial performed in 2020. This nuclear technology uses low specific activity Samarium-153 (resulting in far less europium) and DOTMP, a chelator which is believed to eliminate off-target migration and targets sites of high bone turnover making it an ideal agent to treat osteosarcoma or other bone metastases. Osteosarcoma is the most common malignant bone tumor among children and adolescents. Because of its ability to deliver radiation to the skeletal system, it is also believed to be an effective agent to perform bone marrow ablation as pre-conditioning for bone marrow transplantation. This drug candidate utilizes an FDA-approved radioisotope combined with a novel chelant that has demonstrated increased efficacy and decreased side effects in animal models. Further, CycloSam utilizes a streamlined, just-in-time manufacturing process. Management believes these factors offer a strong pathway to commercialization.
CycloSam is cleared by the FDA under an investigator-initiated IND to commence human dosing immediately in patients with osteosarcoma and bone metastasis. CycloSam was also cleared by the FDA and successfully used under a single-patient IND to perform bone marrow ablation prior to allogenic marrow transplantation (BMA/T) in 2020.
About Checkmate Capital:
Checkmate Capital is an investment group managing family office assets with a geographic focus on North America and Asian-Pacific markets. Checkmate Capital’s primary areas of investment are agricultural bioscience, waste technology, energy technology, biomedical and biotechnology, and diversified special situations. With offices in Pasadena, California and Beijing, China, Checkmate Capital has a team of professionals able to provide seasoned expertise in the group’s focused industries, leveraging an international network of strategic partners, business talent and resources. Checkmate Capital’s strategic oversight facilitates synergistic relationships and technology licensing instrumental to the success of its portfolio companies. For more information, please visit www.checkmatecapital.net.
Legal Notice Regarding Forward-Looking Statements: This news release contains "Forward-looking Statements". These statements relate to future events or our future financial performance. These statements are only predictions and may differ materially from actual future results or events. We disclaim any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise. There are important risk factors that could cause actual results to differ from those contained in forward-looking statements, including, but not limited to our ability to fully commercialize our technology, risks associated with changes in general economic and business conditions, actions of our competitors, the extent to which we are able to develop new products and markets, the time and expense involved in such development activities, the ability to secure additional financing, the ability to consummate acquisitions and ultimately integrate them, the level of demand and market acceptance of our products, and changes in our business strategies. This is not an offering of securities and securities may not be offered or sold absent registration or an applicable exemption from the registration requirements.
Contact
Christopher Nelson
General Counsel
cnelson@qsambio.com
https://www.otcmarkets.com/stock/QSAM/news/QSAM-Biosciences-Closes-Series-B-Preferred-Private-Placement-25-Million-in-New-Capital-to-Fund-Upcoming-Clinical-Trials?id=287882
The corresponding 8-K filed after the close.
Great dip. I think the markets messing up has hurt many today. This is still solid
Great news. I see 5.00 in the future.
$QSAM NEWS OUT —-> QSAM Biosciences Closes Series B Preferred Private Placement; $2.5 Million in New Capital to Fund Upcoming Clinical Trials
1/28/21, 9:00 AM
Austin, Texas, Jan. 28, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation nuclear medicines for the treatment of cancer and related diseases, announced today the successful closing of its Series B Preferred Stock private placement in the amount of $2.5 million. The offering was led by Checkmate Capital Group, LLC (“Checkmate Capital”), an investment firm based in California focused on biotechnology investments and other technologies.
Proceeds from the Series B offering, which was over-subscribed, are expected to be used primarily to fund the Company’s upcoming clinical trials for its flagship drug candidate Samarium-153-DOTMP (aka CycloSam®). The Company expects to file its IND with the U.S. Food and Drug Administration (“FDA”) later this quarter to commence Phase 1 trials shortly thereafter.
“We are very pleased with the overwhelming interest in our offering, the proceeds from which will go directly into advancing the development of CycloSam. We are focused on several important value creating milestones in 2021, including commencement of clinical trials for CycloSam for indications that include both primary bone cancer, such as osteosarcoma, and secondary bone cancers that metastasize from the breast, lung, prostate and other areas. This funding will go a long way towards achieving these and other strategic goals,” stated Douglas R. Baum, CEO and Co-Founder of QSAM.
“We are delighted to participate in this offering as a leading shareholder of QSAM. We have been impressed with the unique attributes of CycloSam’s radiologic cancer therapy, which, in animal studies, has demonstrated deep bone penetration followed by rapid exit of radioactive content from the body, as was reinforced by an FDA-approved, compassionate-use single human application,” commented Tom Paschall, CEO of Checkmate Capital. “We have been further impressed with QSAM’s team of experts in nuclear medicine as well as the leading oncology centers with which QSAM is partnered.”
The Series B preferred shares are convertible into an aggregate of approximately 16.6 million common shares and have voting rights alongside the common holders based on this conversion amount. Investors in the offering also received six-month, non-registered warrants to purchase an aggregate of up to 5.8 million shares of common stock at $0.35 per share. For its early investment and efforts to support the funding, Checkmate Capital received a 12-month warrant for 475,000 shares at $0.45 per share.
The Company also announced that it has moved its official headquarters from Florida to Austin, Texas.
The science is here folks. The proof is in the results. Real company. Real product. Time to make some money.
Some big buys coming through now CSTI way off the ask.
Here we go!!! $QSAM
Once CDEL is finished $1+ coming just have to buy him out. Agree it's close.
I added a chunk today, it’s churning for the next breakout here any moment $QSAM
Adding here .86 chart is green reversal starting. Just need to first break .90 then $1 before news imo.
Like QSAM don't like the selling by CDEL. They probably have a note out or something holding it down but the technology will be a future money maker imo.
These guys have a a buy recommendation from goldman small caps, a PR about better than expected results. These things are huge for a bio tech company. If they get phase 3 clinicals this will become a pricey stock quick
You are witnessing a pump of epic proportions... Don't get caught holding the bag when the DUMP hits!
None of these pumpers are in long term like you are, even if their posting say otherwise.
This is SOP of stocks like CYPW err I mean QPWR err I mean QSAM.. especially after capital raised turns toxic.
I have seen this several times before and the only thing that comes after is a hard crash!
Cash out while you can... keep a little if it makes you sleep better, but don't hold it all and don't buy more at these prices...
-Chuck
CDEL buying a lot on the bid (not to sell lower)
Followers
|
14
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
933
|
Created
|
01/15/08
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |